HC Wainwright Reiterates Neutral Rating for Inhibikase Therapeutics (NYSE:IKT)

Inhibikase Therapeutics (NYSE:IKT)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports.

Inhibikase Therapeutics Trading Down 7.4 %

Shares of NYSE IKT traded down $0.18 during mid-day trading on Friday, hitting $2.20. The company had a trading volume of 40,320 shares, compared to its average volume of 171,426. The firm has a 50-day simple moving average of $2.43 and a two-hundred day simple moving average of $2.38. The company has a market capitalization of $152.25 million, a PE ratio of -0.82 and a beta of 1.04. Inhibikase Therapeutics has a one year low of $1.12 and a one year high of $4.20.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IKT. Soleus Capital Management L.P. acquired a new position in Inhibikase Therapeutics during the fourth quarter worth $20,556,000. Fairmount Funds Management LLC bought a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $19,906,000. ADAR1 Capital Management LLC acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter worth about $16,585,000. Nantahala Capital Management LLC acquired a new position in shares of Inhibikase Therapeutics during the 4th quarter worth about $7,118,000. Finally, Blackstone Inc. bought a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at about $6,730,000. Institutional investors and hedge funds own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.